STOCK TITAN

IIOT-OXYS INC 10-Q Filings

ITOX OTC

Every 10-Q that IIOT-OXYS INC (ITOX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow ITOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ITOX filings page.

Rhea-AI Summary

IIOT-OXYS, Inc. reported no revenue for the three and six months ended June 30, 2026, continuing a pre-revenue profile while focusing on Industrial Internet edge-computing products and services. The company posted a net loss attributable to common stockholders of $1,015,375 for the six months, compared with $230,724 a year earlier.

Cash and cash equivalents declined to $8,651 from $26,342 at year-end 2025, and the company reported a working capital deficit of $3,165,406, total liabilities of $3,188,706, and an accumulated deficit of $13,664,887. Stockholders’ equity was a deficit of $4,350,807. Management states that recurring losses, negative cash flows, and limited liquidity raise substantial doubt about the ability to continue as a going concern and plans to rely on additional borrowings and equity sales, including preferred stock financings with embedded derivative features.

Rhea-AI Summary

IIOT-OXYS, Inc. reported no revenue for the three months ended March 31, 2026 and a net loss attributable to common stockholders of $393,673, up from $180,313 a year earlier, driven mainly by operating expenses and sizable preferred stock dividends of $167,511.

Cash and cash equivalents fell to $6,838 from $26,342 at December 31, 2025, with operating activities using $59,624 of cash. The company had a working capital deficit of $2,653,885, total stockholders’ deficit of $3,726,485, and an accumulated deficit of $13,043,185.

Management states these conditions, along with reliance on external financing, raise substantial doubt about the company’s ability to continue as a going concern. Liquidity has been supported by issuing Series B, C and D convertible preferred stock to GHS Investments, which also created significant derivative liabilities and cumulative preferred dividends, some of which GHS has contractually waived.

Rhea-AI Summary

IIOT-OXYS, Inc. continues to face significant financial strain as of September 30, 2025. The company reported no revenue for the quarter or the first nine months of 2025, compared with $2,500 of revenue in the same nine-month period of 2024. Net loss attributable to common stockholders was $408,889 for the quarter and $669,613 year-to-date, and the company has an accumulated deficit of $11,877,865.

Liquidity is very tight: cash and cash equivalents were only $278, while current liabilities totaled $3,190,356, resulting in a working capital deficit of about $3.19 million and a stockholders’ deficit of $4,015,852. Management discloses that these losses, the cash used in operations, and the deficit raise substantial doubt about the company’s ability to continue as a going concern.

The company is funding itself through high-cost instruments, including Series B, C and D convertible preferred stock with embedded derivatives and convertible notes totaling $393,942 of principal, all classified as current. For the nine months, operating cash outflow was $159,135, partly offset by $141,000 raised from preferred stock sales. A large overhang of potentially issuable shares from convertible securities adds significant dilution risk for common stockholders.

Rhea-AI Summary

IIOT-OXYS, Inc. (ITOX) 10-Q snapshot: The company reported a net loss of $230,724 for the six months ended June 30, 2025 and used $112,726 in operating cash during that period. Management notes an accumulated deficit of $11,438,976 and explicitly states these factors raise substantial doubt about the company’s ability to continue as a going concern. The company remains largely pre-revenue historically, with nominal revenues since 2021.

The balance sheet shows extensive equity and preferred-stock activity: 566,315,293 common shares outstanding at June 30, 2025, multiple series of convertible preferred shares with stated liquidation preferences (Series B approx. $699,600; Series C $68,400; Series D $169,200), and material derivative and mezzanine liabilities related to convertible instruments (derivative liabilities reported at approximately $697,935 at June 30, 2025). Convertible notes and related-party notes carry 12% interest and are secured by substantially all company assets with maturities in early 2026.